SNTI - sentibio.com Forward Price-to-Revenue Multiple

Senti Biosciences, Inc. (SNTI) develops independently of economic cycles, relying instead on its clinical trial timeline. Analyzing the forward P/S chart on GURU.Markets, we note that the metric has leveled off at 77.30. Growth prospects depend on the success of "smart" therapies and partnerships, although the high demand for R&D investment creates certain pressure on the company's current liquidity.

Senti Biosciences - SNTI Projected Price to Revenue (period 04/28/2023 - 11/13/2026)

sentibio.com - analytical breakdowns and key metrics (SNTI)

- market price and analyst price targets:

Price Chart Senti Biosciences|SNTI - Price Target Chart

- market capitalization statistics:

Market Valuation SNTI|SNTI - Value Adjusted for Debt and Cash

- business book valuation details:

Book Value per Share Senti Biosciences|SNTI - Book Value of Business|Market Capitalization to Book Value Ratio sentibio.com|SNTI - Company Assets

- debt and solvency information:

- financial results and valuation multiples details:

SNTI - Final Profit|Projected Future Earnings Senti Biosciences, Inc.|SNTI - Market Cap to Earnings|Future Price to Earnings Senti Biosciences|SNTI - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple SNTI|SNTI - Operating profit EBITDA|Earnings per share for the last twelve months Senti Biosciences|SNTI - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months sentibio.com|SNTI - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Senti Biosciences, Inc.

- revenue and sales proceeds data:

SNTI - Company Gross Revenue|Projected Sales Volume Senti Biosciences|SNTI - Price to Sales|Price-to-Projected Revenue Ratio SNTI

Initial company analysis:Senti Biosciences Inc (SNTI)

When constructing a long-term portfolio, utilizing leading metrics to verify an asset's fair value is critically important. The forward P/S ratio compares current market capitalization with projected revenue, reflecting market expectations for the commercialization of Senti Biosciences, Inc. (SNTI) proprietary logic gene circuits, which allows for an assessment of the premium for technological superiority over CAR-T therapy through the price action of this chart.

Key competitors

Price-to-Projected Revenue Ratio Legend Biotech Corporation LEGN|Sana Biotechnology Inc - Price-to-Projected Revenue Ratio|AUTL: Forward Price-to-Revenue Multiple|Forward Price to Sales ALLO (Allogene Corp)|RNAC: Forward P/S Multiple|Projected Price to Revenue Cellectis CLLS|CRBU (Caribou Biosciences, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Instil Bio Inc. TIL|Price-to-Projected Revenue Ratio Genenta Science S.p.A. (GNTA)|centurytx.com - Market Cap to Projected Revenue|Forward P/S Multiple JSPR (Jasper Therapeutics, Inc.)|Adaptimmune Therapeutics plc (ADAP) - Market Cap to Future Revenue Ratio|CERO: Forward Price-to-Revenue Multiple|Forward Price to Sales TCRT (Alaunos Therapeutics)|ACHL (achillestx.com) - Forward Price-to-Revenue Multiple|CRGX: Price to Expected Revenue Ratio|PSTX (Poseida Therapeutics) - Forward P/S Multiple|TSVT: Forward Price to Sales|Forward P/S Multiple GRCL